Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

Lucía Pérez-Lamas, Adrian Segura Diaz, Elvira Mora, Marta Hidalgo Soto, Antonio Paz Coll, Natalia De Las Heras, Montse Cortes, Patricia Velez Tenza, Magdalena Sierra Pacho, María Alicia Senin, Anna Angona, Carlos Cervero, Raquel De Paz Arias, Araceli Salamanca Cuenca, Marta Santaliestra, Javier López Marin, Luis Felipe Casado Montero, Valentín García Gutiérrez

Blood (2023) 142 (Supplement 1): 3177.

https://doi.org/10.1182/blood-2023-187412

Published: 2023

Journal Articles

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Jasson Villarreal Hernandez, Helena Pomares, Antonella Sturla, Esther Alonso, Clara Maluquer Artigal, Rebecca Andersson, María Alicia Senin, Maria Teresa Encuentra, Mercedes Galiano, Lurdes Zamora, Marta Cabezón, Neus Ruiz Xiville, Maria Carolina Florian, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5868.

https://doi.org/10.1182/blood-2023-187430

Published: 2023

Journal Articles

LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center

Helena Pomares, Iago Arribas, Teresa Quiñones, Jasson Villarreal Hernandez, Julia Ribes Amoros, Clara Maluquer Artigal, Shiomara Quiñones, Maria Isabel Sotelo, María Alicia Senin, Mercedes Galiano, Enric Gamundi, Lurdes Zamora, Neus Ruiz Xiville, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 4225.

https://doi.org/10.1182/blood-2023-178351

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Blood (2023) 142 (Supplement 1): 3163.

https://doi.org/10.1182/blood-2023-188875

Published: 2023

Journal Articles

Venetoclax Exposure Reduction in Venetoclax-Hypomethylating Agents Combination Is Feasible and Has the Same Efficacy in Patients with Acute Myeloblastic Leukemia. Experience of a Single Center

Iago Arribas, Helena Pomares, Teresa Quiñones, Jasson Villarreal Hernandez, Julia Ribes-Amoros, Clara Maluquer Artigal, Shiomara Quiñones, Maria Isabel Sotelo, María Alicia Senin, Mercedes Galiano, Enric Gamundí, Lurdes Zamora, Neus Ruiz Xiville, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5930.

https://doi.org/10.1182/blood-2023-189187

Published: 2023

Journal Articles

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

Blood (2023) 142 (Supplement 1): 6425.

https://doi.org/10.1182/blood-2023-184980

Published: 2023

Journal Articles

Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 12245–12247.

https://doi.org/10.1182/blood-2022-168900

Published: 2022

Journal Articles

Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Blood (2022) 140 (Supplement 1): 6730–6732.

https://doi.org/10.1182/blood-2022-163070

Published: 2022

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Blood (2022) 140 (Supplement 1): 826–827.

https://doi.org/10.1182/blood-2022-158669

Published: 2022

Journal Articles

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Blood (2021) 138 (Supplement 1): 2719.

https://doi.org/10.1182/blood-2021-149192

Published: 2021

Journal Articles

Early Normalization of Serum Free Light Chain (FLC) Assays Correlates with Profound and Prolonged Responses in Newly Diagnosed Multiple Myeloma (MM)

Mercedes Gironella, MD, Alicia Senín, MD, Karla Vallejo, Pamela Arenas, Priyanka Raheja, Romina Dieli, Manuel Hernández, Francesc Bosch, MD

Blood (2018) 132 (Supplement 1): 1897.

https://doi.org/10.1182/blood-2018-99-116475

Published: 2018

Journal Articles

Acquisition of Non-Driver Mutations during Follow-up in Patients with Polycythemia Vera and Essential Thrombocythemia

Alicia Senín, Concepción Fernández Rodríguez, Beatriz Bellosillo, Laura Camacho, Lierni Fernández, Raquel Longarón, Anna Angona, Carlos Besses Raebel, MD PhD, Alberto Alvarez Larran

Blood (2017) 130 (Supplement 1): 2937.

https://doi.org/10.1182/blood.V130.Suppl_1.2937.2937

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Role of Non-Driver Mutations and JAK2 V617F Allele Burden in Myelofibrotic and Acute Myeloid Transformation of Patients with Polycythemia Vera and Essential Thrombocythemia

Alicia Senín, Conchi Fernández, Beatriz Bellosillo, PhD, Laura Camacho, Raquel Longaron, Anna Angona, Sara Montesdeoca, Carlos Besses, Alberto Alvarez-Larrán

Blood (2016) 128 (22): 1952.

https://doi.org/10.1182/blood.V128.22.1952.1952

Published: 2016

Journal Articles

MYD88 (L265P) Mutation Confers Very Poor Response and Outcome after Second-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Antonio Salar, MD, Francesc Garcia-Pallarols, BsC, Concepcion Fernández-Rodríguez, Blanca Sánchez-González, MD, Mari Carmen Vela, Eva Gimeno, Silvia Pairet, Alicia Senin, Laura Camacho, Sergi Serrano, MD PhD, Carlos Besses, Beatriz Bellosillo

Blood (2014) 124 (21): 1690.

https://doi.org/10.1182/blood.V124.21.1690.1690

Published: 2014

Journal Articles

Characterization of CD34+ Hematopoietic Progenitor Cells in JAK2 V617F and Calr- mutated Myeloproliferative Neoplasms

Anna Angona, Alberto Alvarez, Raquel Longarón, Laura Camacho, Concepción Fernández, Silvia Pairet, Luz Martinez, Agueda Ancochea, Alicia Senin, Beatriz Bellosillo, Carlos Besses

Blood (2014) 124 (21): 4572.

https://doi.org/10.1182/blood.V124.21.4572.4572

Published: 2014

NARROW

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Venetoclax Exposure Reduction in Venetoclax-Hypomethylating Agents Combination Is Feasible and Has the Same Efficacy in Patients with Acute Myeloblastic Leukemia. Experience of a Single Center

Retrospective Single Center Descriptive Analysis of a Cohort with Hypereosinophilia Evaluated in the Last Decade

Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Early Normalization of Serum Free Light Chain (FLC) Assays Correlates with Profound and Prolonged Responses in Newly Diagnosed Multiple Myeloma (MM)

Acquisition of Non-Driver Mutations during Follow-up in Patients with Polycythemia Vera and Essential Thrombocythemia

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Role of Non-Driver Mutations and JAK2 V617F Allele Burden in Myelofibrotic and Acute Myeloid Transformation of Patients with Polycythemia Vera and Essential Thrombocythemia

MYD88 (L265P) Mutation Confers Very Poor Response and Outcome after Second-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Characterization of CD34+ Hematopoietic Progenitor Cells in JAK2 V617F and Calr- mutated Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only